Calgranulins may contribute vascular protection in atherogenesis

Circulation Journal

Volumn 78, Issue 2, 2014, Pages 271-280

  Geczy, Carolyn L ^a   Chung, Yuen Ming ^a   Hiroshima, Yuka ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Atherosclerosis; Mast cells; Neutrophils; Redox; S100 proteins

Indexed keywords

ALPHA DEFENSIN; AMYLOID A PROTEIN; AZUROCIDIN; C REACTIVE PROTEIN; CALGRANULIN; CALGRANULIN A; CALGRANULIN B; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; OXIDIZING AGENT; PEROXIDASE; SCAVENGER; TLR4 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; ATHEROGENESIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CELL ADHESION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIAL DYSFUNCTION; EPITHELIUM CELL; FIBROBLAST; GENE CONTROL; HUMAN; INFLAMMATION; MACROPHAGE; MAST CELL; MONOCYTE; NEUTROPHIL; NITROSYLATION; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; ATHEROSCLEROSIS; FOAM CELL; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; FOAM CELLS; FREE RADICAL SCAVENGERS; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; OXIDANTS; PEROXIDASE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84892952706     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1505     Document Type: Review

References (120)

1. Legein B, Temmerman L, Biessen EL, Lutgens E. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci 2013; 70: 3847-3869.
2. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 2045-2051.
3. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res 2012; 110: 875-888.
4. Simon DI, Zidar D. Neutrophils in atherosclerosis: Alarmin evidence of a hit and run? Circ Res 2012; 110: 1036-1038.
5. Ionita MG, van den Borne P, Catanzariti LM, Moll FL, de Vries J-PPM, Pasterkamp G, et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of ruptureprone lesions. Arterioscler Thromb Vasc Biol 2010; 30: 1842-1848.
6. Avanzas P, Quiles J, de Sá EL, Sánchez A, Rubio R, García E, et al. Neutrophil count and infarct size in patients with acute myocardial infarction. Int J Cardiol 2004; 97: 155-156.
7. Mazor R, Shurtz-Swirski R, Farah R, Kristal B, Shapiro G, Dorlechter F, et al. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis 2008; 197: 937-943.
8. Rees MD, Dang L, Thai T, Owen DM, Malle E, Thomas SR. Targeted subendothelial matrix oxidation by myeloperoxidase triggers myosin II-dependent de-adhesion and alters signalling in endothelial cells. Free Radic Biol Med 2012; 53: 2344-2356.
9. Megens RTA, Vijayan S, Lievens D, Döring Y, van Zandvoort MAMJ, Grommes J, et al. Presence of luminal neutrophil extracellular traps in atherosclerosis. Thromb Haemost 2012; 107: 597-598.
10. Soehnlein O, Wantha S, Simsekyilmaz S, Döring Y, Megens RTA, Mause SF, et al. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med 2011; 3: 103ra98.
11. Hsu K, Champaiboon C, Guenther BD, Sorenson BS, Khammanivong A, Ross KF, et al. Anti-infective protective properties of S100 calgranulins. Antiinflamm Antiallergy Agents Med Chem 2009; 8: 290-305.
12. Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calciumbinding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004; 344: 37-51.
13. Perera C, McNeil HP, Geczy CL. S100 calgranulins in inflammatory arthritis. Immunol Cell Biol 2010; 88: 41-49.
14. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
15. Ravasi T, Hsu K, Goyette J, Schroder K, Yang Z, Rahimi F, et al. Probing the S100 protein family through genomic and functional analysis. Genomics 2004; 84: 10-22.
16. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009; 86: 557-566.
17. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 2009; 5: e1000639, doi:10.1371/journal.ppat.1000639.
18. Korndörfer IP, Brueckner F, Skerra A. The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting a-helices can determine specific association of two EF-hand proteins. J Mol Biol 2007; 370: 887-898.
19. Endoh Y, Chung YM, Clark IA, Geczy CL, Hsu K. IL-10-dependent S100A8 gene induction in monocytes/macrophages by doublestranded RNA. J Immunol 2009; 182: 2258-2268.
20. Hsu K, Passey RJ, Endoh Y, Rahimi F, Youssef P, Yen T, et al. Regulation of S100A8 by glucocorticoids. J Immunol 2005; 174: 2318-2326.
21. Passey RJ, Williams E, Lichanska AM, Wells C, Hu S, Geczy CL, et al. A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol 1999; 163: 2209-2216.
22. Xu K, Yen T, Geczy CL. IL-10 up-regulates macrophage expression of the S100 protein S100A8. J Immunol 2001; 166: 6358-6366.
23. Lim SY, Raftery M, Cai H, Hsu K, Yan WX, Hseih H-L, et al. SNitrosylated S100A8: Novel anti-inflammatory properties. J Immunol 2008; 181: 5627-5636.
24. Bozinovski S, Cross M, Vlahos R, Jones JE, Hsu K, Tessier PA, et al. S100A8 chemotactic protein is abundantly increased, but only a minor contributor to LPS-induced, steroid resistant neutrophilic lung inflammation in vivo. J Proteome Res 2005; 4: 136-145.
25. Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, et al. S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: Implications for atherosclerosis and adipose tissue inflammation. Circulation 2011; 123: 1216-1226.
26. Yen T, Harrison CA, Devery JM, Leong S, Iismaa SE, Yoshimura T, et al. Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood 1997; 90: 4812-4821.
27. McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, Cai H, et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem 2005; 280: 41521-41529.
28. Rahimi F, Hsu K, Endoh Y, Geczy CL. FGF-2, IL-1beta, and TGFbeta regulate fibroblast expression of S100A8. FEBS J 2005; 272: 2811-2827.
29. Grimbaldeston MA, Geczy CL, Tedla N, Finlay-Jones JJ, Hart PH. S100A8 induction in keratinocytes by ultraviolet A irradiation is dependent on reactive oxygen intermediates. J Invest Dermatol 2003; 121: 1168-1174.
30. Kerkhoff C, Voss A, Scholzen TE, Averill MM, Zänker KS, Bornfeldt KE. Novel insights into the role of S100A8/A9 in skin biology. Exp Dermatol 2012; 21: 822-826.
31. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001; 69: 986-994.
32. Hasegawa T, Kosaki A, Kimura T, Matsubara H, Mori Y, Okigaki M, et al. The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. Atherosclerosis 2003; 171: 211-218.
33. Kido J, Kido R, Suryono, Kataoka M, Fagerhol MK, Nagata T. Calprotectin release from human neutrophils is induced by Porphyromonas gingivalis lipopolysaccharide via the CD-14-Toll-like receptor-nuclear factor kappaB pathway. J Periodontal Res 2003; 38: 557-563.
34. Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 2013; 52: 45-52.
35. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: A controlled study. Am J Hypertens 2012; 25: 644-650.
36. Tydén H, Lood C, Gullstrand B, Jönsen A, Nived O, Sturfelt G, et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford) 2013; 52: 2048-2055.
37. Hara M, Ando M, Morito T, Nokiba H, Iwasa Y, Tsuchiya K, et al. S100A12 gene expression is increased in peripheral leukocytes in chronic kidney disease stage 4-5 patients with cardiovascular disease. Nephron Clin Pract 2013; 123: 202-208.
38. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, et al. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009; 29: 18-24.
39. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, et al. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 718-723.
40. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012; 220: 208-214.
41. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Barany P, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 2213-2219.
42. Goyette J, Yan WX, Yamen E, Chung YM, Lim SY, Hsu K, et al. Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J Immunol 2009; 183: 593-603.
43. Katashima T, Naruko T, Terasaki F, Fujita M, Otsuka K, Murakami S, et al. Enhanced expression of the S100A8/A9 complex in acute myocardial infarction patients. Circ J 2010; 74: 741-748.
44. Ionita MG, Vink A, Dijke IE, Laman JD, Peeters W, van der Kraak PH, et al. High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of ruptureprone lesions. Arterioscler Thromb Vasc Biol 2009; 29: 1220-1227.
45. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K, et al. Platelet expression profiling and clinical validation of myeloidrelated protein-14 as a novel determinant of cardiovascular events. Circulation 2006; 113: 2278-2284.
46. Vora AN, Bonaca MP, Ruff CT, Jarolim P, Murphy S, Croce K, et al. Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. J Thromb Thrombolysis 2012; 34: 229-234.
47. Abbas A, Aukrust P, Dahl TB, Bjerkeli V, Sagen EB, Michelsen A, et al. High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis. Stroke 2012; 43: 1347-1353.
48. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: A postmortem study. Arterioscler Thromb Vasc Biol 2004; 24: 1266-1271.
49. Hofmann Bowman M, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA, et al. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 2010; 106: 145-154.
50. Croce K. S100A8/A9 complex: More than just a biomarker of cardiovascular risk? Circ J 2010; 74: 626-627.
51. Averill MM, Kerkhoff C, Bornfeldt KE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 2012; 32: 223-229.
52. Lim SY, Raftery MJ, Geczy CL. Oxidative modifications of DAMPs suppress inflammation: The case for S100A8 and S100A9. Antioxid Redox Signal 2011; 15: 2235-2248.
53. Kerkhoff C, Nacken W, Benedyk M, Dagher MC, Sopalla C, Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J 2005; 19: 467-469.
54. Hofmann Bowman MA, Gawdzik J, Bukhari U, Husain AN, Toth PT, Kim G, et al. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol 2011; 31: 337-344.
55. Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 2003; 23: 1034-1043.
56. Eue I, Langer C, Eckardstein A, Sorg C. Myeloid related protein (MRP) 14 expressing monocytes infiltrate atherosclerotic lesions of ApoE null mice. Atherosclerosis 2000; 151: 593-597.
57. Croce K, Gao H, Wang Y, Mooroka T, Sakuma M, Shi C, et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 2009; 120: 427-436.
58. Johansson F, Kramer F, Barnhart S, Kanter JE, Vaisar T, Merrill RD, et al. Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc Natl Acad Sci USA 2008; 105: 2082-2087.
59. New SE, Goettsch C, Aikawa M, Marchini JF, Shibasaki M, Yabusaki K, et al. Macrophage-derived matrix vesicles: An alternative novel mechanism for microcalcification in atherosclerotic plaques. Circ Res 2013; 113: 72-77.
60. Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, et al. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med 2010; 153: 425-434.
61. Das D, Gawdzik J, Dellefave-Castillo L, McNally EM, Husain A, Raman J, et al. S100A12 expression in thoracic aortic aneurysm is associated with increased risk of dissection and perioperative complications. J Am Coll Cardiol 2012; 60: 775-785.
62. Hofmann Bowman MA, McNally EM. Genetic pathways of vascular calcification. Trends Cardiovasc Med 2012; 22: 93-98.
63. Isaksen B, Fagerhol MK. Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Mol Pathol 2001; 54: 289-292.
64. Goyette J, Geczy CL. Inflammation-associated S100 proteins: New mechanisms that regulate function. Amino Acids 2011; 41: 821-842.
65. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, et al. Functions of S100 proteins. Curr Mol Med 2013; 13: 24-57.
66. Lackmann M, Rajasekariah P, Iismaa SE, Jones G, Cornish CJ, Hu S, et al. Identification of a chemotactic domain of the pro-inflammatory S100 protein CP-10. J Immunol 1993; 150: 2981-2991.
67. McNeill E, Conway SJ, Roderick HL, Bootman MD, Hogg N. Defective chemoattractant-induced calcium signalling in S100A9 null neutrophils. Cell Calcium 2007; 41: 107-121.
68. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-1049.
69. Foell D, Wittkowski H, Kessel C, Luken A, Weinhage T, Varga G, et al. Proinflammatory S100A12 can activate human monocytes via toll-like receptor 4. Am J Respir Crit Care Med 2013; 187: 1324-1334.
70. Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J, et al. Increased proinflammatory endothelial response to S100A8/ A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol 2006; 5: 6.
71. Viemann D, Barczyk K, Vogl T, Fischer U, Sunderkotter C, Schulze-Osthoff K, et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and-independent cell death program. Blood 2007; 109: 2453-2460.
72. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
73. Inaba H, Hokamura K, Nakano K, Nomura R, Katayama K, Nakajima A, et al. Upregulation of S100 calcium-binding protein A9 is required for induction of smooth muscle cell proliferation by a periodontal pathogen. FEBS Lett 2009; 583: 128-134.
74. Sroussi HY, Berline J, Dazin P, Green P, Palefsky JM. S100A8 triggers oxidation-sensitive repulsion of neutrophils. J Dent Res 2006; 85: 829-833.
75. Sroussi HY, Lu Y, Zhang QL, Villines D, Marucha PT. S100A8 and S100A9 inhibit neutrophil oxidative metabolism in-vitro: Involvement of adenosine metabolites. Free Radic Res 2010; 44: 389-396.
76. Rezvanpour A, Shaw GS. Unique S100 target protein interactions. Gen Physiol Biophys 2009; 28: F39-F46.
77. Yan WX, Armishaw C, Goyette J, Yang Z, Cai H, Alewood P, et al. Mast cell and monocyte recruitment by S100A12 and its hinge domain. J Biol Chem 2008; 283: 13035-13043.
78. Xie J, Burz DS, He W, Bronstein IB, Lednev I, Shekhtman A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem 2007; 282: 4218-4231.
79. Moroz O, Burkitt W, Wittkowski H, He W, Ianoul A, Novitskaya V, et al. Both Ca2+ and Zn2+ are essential for S100A12 proteinoligomerization and function. BMC Biochem 2009; 10: 11.
80. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009; 7: e97, doi:10.1371/journal.pbio.1000097.
81. Riva M, Kallberg E, Bjork P, Hancz D, Vogl T, Roth J, et al. Induction of nuclear factor-kappaB responses by the S100A9 protein is Toll-like receptor-4-dependent. Immunology 2012; 137: 172-182.
82. Chung YM, Goyette J, Tedla N, Hsu K, Geczy CL. S100A12 suppresses pro-inflammatory, but not pro-thrombotic functions of serum amyloid A. PLoS One 2013; 8: e62372, doi:10.1371/journal.pone.0062372.
83. Brun JG, Haland G, Haga HJ, Fagerhol MK, Jonsson R. Effects of calprotectin in avridine-induced arthritis. APMIS 1995; 103: 233-240.
84. Ikemoto M, Murayama H, Itoh H, Totani M, Fujita M. Intrinsic function of S100A8/A9 complex as an anti-inflammatory protein in liver injury induced by lipopolysaccharide in rats. Clin Chim Acta 2007; 376: 197-204.
85. Otsuka K, Terasaki F, Ikemoto M, Fujita S, Tsukada B, Katashima T, et al. Suppression of inflammation in rat autoimmune myocarditis by S100A8/A9 through modulation of the proinflammatory cytokine network. Eur J Heart Fail 2009; 11: 229-237.
86. Sun Y, Lu Y, Engeland CG, Gordon SC, Sroussi HY. The antioxidative, anti-inflammatory, and protective effect of S100A8 in endotoxemic mice. Mol Immunol 2013; 53: 443-449.
87. Shimizu K, Libby P, Rocha VZ, Folco EJ, Shubiki R, Grabie N, et al. Loss of myeloid related protein-8/14 exacerbates cardiac allograft rejection. Circulation 2011; 124: 2920-2932.
88. Petersen B, Wolf M, Austermann J, van Lent P, Foell D, Ahlmann M, et al. The alarmin Mrp8/14 as regulator of the adaptive immune response during allergic contact dermatitis. EMBO J 2013; 32: 100-111.
89. Raftery MJ, Yang Z, Valenzuela SM, Geczy CL. Novel intra-and inter-molecular sulfinamide bonds in S100A8 produced by hypochlorite oxidation. J Biol Chem 2001; 276: 33393-33401.
90. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: Involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 1309-1314.
91. Gomes LH, Raftery MJ, Yan WX, Goyette JD, Thomas PS, Geczy CL. S100A8 and S100A9-oxidant scavengers in inflammation. Free Radic Biol Med 2013; 58: 170-186.
92. Sroussi HY, Berline J, Palefsky JM. Oxidation of methionine 63 and 83 regulates the effect of S100A9 on the migration of neutrophils in vitro. J Leukoc Biol 2007; 81: 818-824.
93. Lim SY, Raftery MJ, Goyette J, Geczy CL. S-glutathionylation regulates inflammatory activities of S100A9. J Biol Chem 2010; 285: 14377-14388.
94. Anceriz N, Vandal K, Tessier PA. S100A9 mediates neutrophil adhesion to fibronectin through activation of beta2 integrins. Biochem Biophys Res Commun 2007; 354: 84-89.
95. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: Proteins S100A8, S100A9, and S100A8/ A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003; 170: 3233-3242.
96. Bot I, Biessen EA. Mast cells in atherosclerosis. Thromb Haemost 2011; 106: 820-826.
97. Wang Y, Shi GP. Mast cell chymase and tryptase in abdominal aortic aneurysm formation. Trends Cardiovasc Med 2012; 22: 150-155.
98. Ramalho LS, Oliveira LF, Cavellani CL, Ferraz ML, de Oliveira FA, Miranda Correa RR, et al. Role of mast cell chymase and tryptase in the progression of atherosclerosis: Study in 44 autopsied cases. Ann Diagn Pathol 2013; 17: 28-31.
99. Hofmann Bowman MA, Schmidt AM. S100/calgranulins ENRAGEing the blood vessels: Implications for inflammatory responses and atherosclerosis. Am J Cardiovasc Dis 2011; 1: 92-100.
100. Hofmann Bowman MA, Heydemann A, Gawdzik J, Shilling RA, Camoretti-Mercado B. Transgenic expression of human S100A12 induces structural airway abnormalities and limited lung inflammation in a mouse model of allergic inflammation. Clin Exp Allergy 2011; 41: 878-889.
101. Yang Z, Yan WX, Cai H, Tedla N, Armishaw C, Di Girolamo N, et al. S100A12 provokes mast cell activation: A potential amplification pathway in asthma and innate immunity. J Allergy Clin Immunol 2007; 119: 106-114.
102. Zhao J, Endoh I, Hsu K, Tedla N, Endoh Y, Geczy CL. S100A8 modulates mast cell function and suppresses eosinophil migration in acute asthma. Antioxid Redox Signal 2011; 14: 1589-1600.
103. Hess DT, Matsumoto A, Kim S-O, Marshall HE, Stamler JS. Protein S-nitrosylation: Purview and parameters. Nat Rev Mol Cell Biol 2005; 6: 150-166.
104. Kubes P. Inducible nitric oxide synthase: A little bit of good in all of us. Gut 2000; 47: 6-9.
105. Maskrey BH, Megson IL, Whitfield PD, Rossi AG. Mechanisms of resolution of inflammation: A focus on cardiovascular disease. Arterioscler Thromb Vasc Biol 2011; 31: 1001-1006.
106. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
107. Tolle M, Huang T, Schuchardt M, Jankowski V, Prufer N, Jankowski J, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 2012; 94: 154-162.
108. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function. Proc Natl Acad Sci USA 1994; 91: 3186-3190.
109. Dong Z, Wu T, Qin W, An C, Wang Z, Zhang M, et al. Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol Med 2011; 17: 1357-1364.
110. Furlaneto CJ, Campa A. A novel function of serum amyloid A: A potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 2000; 268: 405-408.
111. Song C, Hsu K, Yamen E, Yan W, Fock J, Witting PK, et al. Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 2009; 207: 374-383.
112. Ribeiro FP, Furlaneto CJ, Hatanaka E, Ribeiro WB, Souza GM, Cassatella MA, et al. mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes. Mediators Inflamm 2003; 12: 173-178.
113. Yavin EJ, Preciado-Patt L, Rosen O, Yaron M, Suessmuth RD, Levartowsky D, et al. Serum amyloid A-derived peptides, present in human rheumatic synovial fluids, induce the secretion of interferong by human CD4+ T-lymphocytes. FEBS Lett 2000; 472: 259-262.
114. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, et al. Acute-phase serum amyloid A: An inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006; 3: e287, doi:10.1371/journal.pmed.0030287.
115. Mullan RH, McCormick J, Connolly M, Bresnihan B, Veale DJ, Fearon U. A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A. Am J Pathol 2010; 176: 1999-2008.
116. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994; 180: 203-209.
117. Olsson N, Siegbahn A, Nilsson G. Serum amyloid A induces chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway. Biochem Biophys Res Commun 1999; 254: 143-146.
118. Cai H, Song C, Endoh I, Goyette J, Jessup W, Freedman SB, et al. Serum amyloid A induces monocyte tissue factor. J Immunol 2007; 178: 1852-1860.
119. Witting PK, Song C, Hsu K, Hua S, Parry SN, Aran R, et al. The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein. Free Radic Biol Med 2011; 51: 1390-1398.
120. Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2008; 295: H2399-H2408.